Ruthenium complexes, [Ru(bpy)2(DMSO)Cl]PF6 and [Ru(tpa)(DMSO)Cl](Clo4) as Potential Photodynamic Therapeutic Agents
Master of Science
Ruthenium complexes have been developed to overcome the cellular resistance developed against the well-known anti-cancer drug Cisplatin. Cisplatin has a limited activity against most common forms of breast and gastrointestinal tumors. In this research, octahedral Ruthenium complexes were synthesized and characterized. Various strategies have been employed to improve the sequence selectivity of cleavage which can arise from preferential binding at a certain site. DNA binding and photocleavage properties of these complexes are reported. Both the complexes have their absorbance maximum in the visible region (415 nm). Cancer cells have lower pH and generally hypoxic compared to the normal cells. Ruthenium complexes are inactive and non-reactive until they enter the cancer cells where they are reduced to more active forms (activation by reduction). For the compounds to be active in vivo, the complexes must have a biologically accessible reduction potential, which can vary with the ligands present. Ruthenium complexes are able to bind to the DNA forming adducts which block the DNA and RNA synthesis and induce apotosis programmed cell death. Upon irradiation, [Ru(bpy)2(DMSO)cl]PF6 is capable to photocleave plasmid DNA. In contrast [Ru(tpa)(DMSO)Cl](Clo4) did not cleave the plasmid DNA under similar irradiation conditions. Cytotoxicity and phototoxicity of these Ruthenium complexes towards the human skin fibroblast cells were measured and the LD50 is calculated.
Banda, Srikanth Reddy, "Ruthenium complexes, [Ru(bpy)2(DMSO)Cl]PF6 and [Ru(tpa)(DMSO)Cl](Clo4) as Potential Photodynamic Therapeutic Agents" (2010). All Capstone Projects. 391.